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Abstract
Monte Carlo (MC)‐based dose calculations are generally superior to analytical dose calcula-
tions (ADC) in modeling the dose distribution for proton pencil beam scanning (PBS) treat-
ments. The purpose of this paper is to present a methodology for commissioning and
validating an accurate MC code for PBS utilizing a parameterized source model, including an
implementation of a range shifter, that can independently check the ADC in commercial treat-
ment planning system (TPS) and fast Monte Carlo dose calculation in opensource platform
(MCsquare). The source model parameters (including beam size, angular divergence and
energy spread) and protons per MU were extracted and tuned at the nozzle exit by comparing
Tool for Particle Simulation (TOPAS) simulations with a series of commissioning measure-
ments using scintillation screen/CCD camera detector and ionization chambers. The range
shifter was simulated as an independent object with geometric and material information. The
MC calculation platform was validated through comprehensive measurements of single spots,
field size factors (FSF) and three‐dimensional dose distributions of spread‐out Bragg peaks
(SOBPs), both without and with the range shifter. Differences in field size factors and absolute
output at various depths of SOBPs between measurement and simulation were within 2.2%,
with and without a range shifter, indicating an accurate source model. TOPAS was also vali-
dated against anthropomorphic lung phantom measurements. Comparison of dose distribu-
tions and DVHs for representative liver and lung cases between independent MC and
analytical dose calculations from a commercial TPS further highlights the limitations of the
ADC in situations of highly heterogeneous geometries. The fast MC platform has been imple-
mented within our clinical practice to provide additional independent dose validation/QA of
the commercial ADC for patient plans. Using the independent MC, we can more efficiently
commission ADC by reducing the amount of measured data required for low dose “halo”
modeling, especially when a range shifter is employed.
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1 | INTRODUCTION
The use of Pencil Beam Scanning (PBS) is expanding rapidly in pro-
ton therapy, in large part because the approach produces highly con-
formal dose distributions and facilitates optimized delivery, without
the requirement of field‐specific hardware such as compensators or
apertures, in contrast to conventional double scattering and uniform
scanning delivery. At the University of Pennsylvania Roberts Proton
Therapy Center, PBS delivery has been implemented for clinical
treatment on two universal nozzles and one dedicated nozzle.
MC‐based dose calculation is generally superior to analytical
algorithms commonly used in treatment planning system (TPS) in
modeling the dose distribution for PBS treatments.1–3 This is particu-
larly true when protons propagate through bone–soft tissue, soft tis-
sue–air, and bone–air interfaces in treatment sites such as head and
neck and lung, as multiple Coulomb scattering (MCS) can lead to a
distortion of the field and inadequate target coverage.2,3
While PBS eliminates most patient specific hardware, a beam
modifier is still required in some situations. Various technical con-
straints in the current delivery systems result in a minimum proton
energy limitation of between 70 and 100 MeV,4 thus a range shifter
is needed to degrade the proton range in order to treat tumors
located shallower than the minimum range.5 It is well known that the
energy spread (due to energy straggling) and spot size (due to MCS)
increase at the exit of a range shifter.6 To minimize the spot broaden-
ing, the air gap between the range shifter and patient should be as
small as possible, though the potential for collision with the patient
often requires a gap that is larger than physically optimal. Due to the
generation of secondary products as well as the particle transport
within the air gap, it is difficult to model the dose calculation with a
range shifter analytically given a limited measured data set,5 thus an
approach such as MC is desirable; the broader MC generated dataset
is valuable for analytically approximating the low‐dose halo5 using
multi‐Gaussian lookup tables in water or in air after a range shifter
given the magnification of potential MCS and halo calculation inaccu-
racies by various range shifter thicknesses and air gaps.7,8
For any MC dose calculation, the first step is always to construct
an accurate source model to parameterize the proton's distribution
information in phase space (beam size, angular divergence and energy
spread) at the position where it enters the simulated area. Several
papers9–11 have reported how to develop such beam source model
by deriving source parameters through a set of simple measurements
for individual beam lines. The major advantage is that this does not
require knowledge of beam line or nozzle components and material
compositions, and hence significantly reduces computing time with-
out the need to model the nozzle. As the halo caused by the range
shifter is intrinsically different from a halo in vacuum, a proper char-
acterization of the halo component of the beam, below a factor of
10−4 of the central axis dose is necessary,12 as is a double‐Gaussian
fluence model,8 to avoid dose inaccuracies. Hence, the range shifter
in this paper is included as part of the simulated area as described by
Grevillot10 rather than creating an additional source model. The
methodology is subsequently validated using a comprehensive set of
measurements in water, both without and with range shifter to
emphasize role of the low‐dose halo, and also an anthropomorphic
lung phantom for dose accuracy in heterogeneous medium.
The aim of this work is to develop and validate an accurate dose
calculation platform based on TOPAS13 that can be used to config-
ure and validate both commercial14,15 and in‐house16,17 fast MC
dose calculation algorithms for PBS treatment. Validation and clinical
implementation of fast MC can potentially facilitate routine treat-
ment plan quality assurance,18,19 and bring 4D dynamic dose
(4DDD) MC engines from conceptual research to clinical prac-
tices,20–22 when the dosimetric accuracy of analytical dose engines
are challenged for the cases of heterogeneous tissue or with involve-
ment of range shifter/patient bolus and large air gap.
2 | MATERIALS AND METHODS
2.A | Source model
The design of the dedicated PBS nozzle (IBA Particle Therapy, Lou-
vain‐la‐Neuve, Belgium; model: Dedicated Pencil Beam Nozzle) used
in this study has been described by Farr4 and Lin.23 A schematic
view of the nozzle system is presented in Fig. 1. In this section, we
describe how the source model parameters are determined based on
a set of reference measurements.
2.A.1 | Modeling the beam optics
The model uses the IEC61217 gantry coordinate system, where the
source plane is on the positive z‐axis and the origin is at isocenter.
The source plane is set at the upstream surface of the range shifter
to ensure that the range shifter can be correctly calculated when
used in treatment (Fig. 1). A parameterization of the source model at
the source plane is therefore required, including the spatial beam
spread distribution (beam spot size), σx, and the angular spread distri-
bution (beam divergence), σxθ , as well as the coefficient of correla-
tion ρx (the same relation holds for the y‐direction). According to
Courant–Snyder's particle transportation theory,24 the σ-matrix of a
beam's parameters at any location Z along the beam path, neglecting
dissipation and diffusion processes, can be described as
σ2x ρxσxσxθ
ρxσxσxθ σ
2
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from which we infer that the variance of the spot size along the
beam path should satisfy
σ2x ðZÞ ¼ σ2x ð0Þ  2ρxð0Þσxð0Þσθð0ÞZ þ σ2xθð0ÞZ2 (2)
Spot profiles at six locations in air along the Z‐axis (455, 330,
200, 100, 0, and −100 mm) were acquired using a scintillation
screen/CCD camera detector (Lynx® — IBA Dosimetry, Schwarzen-
bruck, Germany) with a 0.5‐mm resolution25 for proton energies
from 100 to 220 in 10‐MeV steps plus 115 and 225 MeV. Corre-
sponding parameters at isocenter σxð0Þ; ρxð0Þ and σxθð0Þ were
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derived by fitting the spot size to location Z with Eq. (2). The spot
size at any Z plane, such as the source plane, can be calculated using
Eq. (2), while coefficient of correlation can be calculated from
ρxðZÞ ¼
ρxð0Þσxð0Þ  σxθð0ÞZ
σxðZÞ (3)
which is positive for a defocusing beam and negative for a focusing
beam. Although σθ increases slightly with propagation in air due to
MCS, we approximate it as a constant in air between the nozzle exit
and the phantom surface. The beam optic parameters above are
derived to reproduce the measured spot variance in air which has
taken into account the slightly increased divergence due to the scat-
tering effect of air. The space between source plane and the simu-
lated object, therefore, is set to vacuum in the MC simulation.
In contrast to the parallel scanning PBS system at PSI,4 the IBA
PBS systems have small incident angles according to spot scanning
location. The initial scanning angle and projected offset coordinate
at the source plane (see Fig. 1) for each scanned spot is modeled by
applying two effective focal points with a distance of
fx = 1859.1 mm and fy = 2234.8 mm to the axis in X and Y direction
respectively, which are extracted from measurements of the beam
position at two planes for different beam deflections.11
2.A.2 | Modeling the beam energy spectrum
A Gaussian distribution, with a sigma defined in terms of a percent-
age of the mean energy value, tuned to reproduce the measured
depth‐dose distribution in water, was applied to the energy spec-
trum.10,26 The relative integral Bragg peak curves were collected in a
water phantom for protons entering the center of a Bragg peak
chamber (Model 34070, PTW, Freiburg, Germany) with a diameter
of 81.6 mm, for proton energies from 100 to 220 MeV in 10 MeV
steps plus 115 and 225 MeV. The conversion of measured range to
an initial mean energy was performed using the NIST PSTAR data-
base,27 as described in Grevillot et al.28 The geometry of the scoring
stack in the MC simulations was set to have the same diameter as
the Bragg Peak chamber and a thickness resolution of 0.5 mm. With
the beam optic properties and initial mean energy derived previously,
different energy spreads with 0.05 MeV resolution were simulated
to determine the optimal choice by evaluating the dose‐to‐peak ratio
and mean point‐to‐point dose for each nominal energy10,26; the
mean energy was further tuned to achieve a good range agreement
with measurement. Relative dose comparison between simulated
and measured depth‐dose profiles normalized to the integral dose
deposited was performed.
2.A.3 | Modeling protons per MU
The reference dosimetry approach proposed by Gomà et al.29 was
used to determine protons per MU; 1 MU corresponds to 3 nC col-
lected in a 10 mm gap air‐filled ionization chamber on the IBA proton
therapy systems. The absolute dose was measured using a monoener-
getic beam of 625 spots scanned over 100 × 100 mm2 with 1 MU per
spot and 4‐mm spot spacing at isocenter an entry plateau depth of
42 mm using an parallel plate chamber with a diameter of 16 mm and
0.2‐mm active cylinder height (PPC40, IBA Dosimetry, Schwarzen-
bruck, Germany), for proton energies from 100 to 225 MeV in 5 MeV
intervals. For each of the energies, we simulated the same setup with
specified protons per spot ðNMC ¼ 105Þ and a grid resolution of
1 × 1 × 1 mm3 in a 400 × 400 × 400 mm3 water phantom. Average
dose (DMC) in the central 16 × 16 mm
2 square at depth of 42 mm was
extracted, and the number of protons per MU is defined as:
NMU ¼ DMeasDMC=NMC (4)
where DMeas is the dose measured by ionization chamber. Fracchiolla
et al.26 have reported that the difference in protons per MU between
this approach and that using a Faraday cup is 0.5% on average.
From 2.1.1 to 2.1.3 the beam optic parameters, mean energy,
energy spread and protons per MU were derived for selected mea-
sured energies for which a look‐up table was generated; for other
intermediate energies, where measurements were not available, val-
ues were generated via linear interpolation.
2.A.4 | Modeling the range shifter
In the range shifter modeling approach of Fracchiolla et al.,26 the
beam model is tuned following the same procedure as for the open‐
field model characterization. This requires twice the time and
F I G . 1 . Schematic design of a general
scanning system with range shifter. fx and
fx represent the effective source axis
distance in X and Y direction respectively.
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number of measurements for the Bragg peak curves and spot pro-
files. The interaction of the protons with the range shifter generates
additional secondary particles resulting in a larger halo; propagation
through the air gap between range shifter and patient will create sig-
nificant difficulties for both experiment and simulation.5 To address
these challenges, we simulate the range shifter as an object within
the beam path as described by Grevillot,10 specifying its geometry
dimension, material composition, mass density, and mean excitation
energy. The dedicated nozzle has a 65‐mm thick Lexan range shifter
with water equivalent thickness 74.1 mm (modeled with elemental
compositions of carbon 75.575%, oxygen 18.876% and hydrogen
5.549%; mass density 1.20 g/cm3 and mean excitation energy of
73.1 eV from the NIST PSTAR database27) installed at the end of
nozzle exit.
2.B | Model validation measurements
Initial benchmark measurements were performed to validate the MC
model for single spots. The Lynx® device was used to measure single
spot profiles without a range shifter for energies 100, 115, 150, 180,
and 210 MeV at different depths in Solid Water® (Gammex, Inc.,
Wisconsin, USA), with the surface at isocenter without the range
shifter. In‐air single spot profiles for energies of 115, 150, 180, and
210 MeV were measured at different air gaps following the range
shifter.
Rather than a detailed single‐spot profile validation of the
halo,7,12,30–32 field size factors (FSF) for square fields with 4 mm
spacing and 1 MU per spot of monoenergetic proton beams,
described by Pedroni et al.,4 Sawakuchi et al.,33 Zhu et al.,34 and
Shen et al,35 were used to investigate the accuracy of the halo both
with and without the range shifter. A water phantom (Digiphant,IBA
Dosimetry, Schwarzenbruck, Germany), which combines a two‐
dimensional ionization chamber array (MatriXX PT®, IBA Dosimetry,
Schwarzenbruck, Germany) dedicated to address the high‐dose rates
in PBS, in a waterproof housing that can be scanned in a water
phantom, was used to measure the two‐dimensional (2D) dose distri-
butions in selected depth perpendicular to the beam incident direc-
tion.36 Measurements without the range shifter were obtained with
the water phantom surface at isocenter and with an air gap of
150 mm to the range shifter.
Lastly, absolute output calculated by MC was validated using
central axis dose measurements at different depths in water for
three multi‐energy PBS beams (RxMy, with nominal range of x mm
and nominal modulation of y mm) at a field size of 96 × 96 mm
using the Digiphant®, both without and with range shifter. A parallel
plate ionization chamber (PPC40, IBA dosimetry) was used to cross-
check the absolute output of the MatriXXPT for each measured
dataset. Furthermore, lateral dose profiles were measured using the
Lynx device at the mid SOBP in the Solid Water phantom. Due to
concern of the scintillator's energy‐dependent response,27 Lynx mea-
surements with higher resolution were limited to relative dose distri-
butions that involve minimal energy variation. Furthermore, an
anthropomorphic left lung heterogeneous phantom, provided by the
Imaging and Radiation Oncology Core (IROC) Houston Quality
Assurance Center, was used to test the MC dose calculation algo-
rithm in clinical conditions. Devices used for measurements included
two thermoluminescent dosimeters (TLD) for absolute dose in the
center of the target, and Gafchromic EBT 3 films (Ashland, Dublin,
OH) for high resolution profile measurements in the axial, sagittal,
and coronal planes. The dose profiles from the films were then
scaled to the corresponding TLD doses. The three‐dimensional dose
distributions calculated by both ADC from a commercial TPS and
independent MC (TOPAS) were submitted to IROC Houston to com-
pare with film measurements over three cross‐section views for
gamma index analysis.
2.C | Monte Carlo simulation and clinical
application
The MC algorithm used is TOPAS (Version 2.0 built on Gean-
t4.10.1p02), which provides advanced features for source model, com-
plex geometry management, patient CT DICOM image processing
with user‐defined calibration curves in terms of material composition
and density, as well as multi‐threaded calculation. The default physics
list containing the Geant4 modules (tsem‐standard_opt3_WVI, g4 h‐
phy_QGSP_BIC_HP, g4decay, g4ion‐binarycascade, g4 h‐elastic_HP,
and g4qstopping) in TOPAS was used in the simulations without modi-
fication. The mean excitation energy of water was set at 75.0 eV, and
Solid Water material was modeled according to the vendor‐supplied
specifications with elemental compositions of carbon 67.17%, oxygen
19.88%, hydrogen 8.09%, nitrogen 2.41%, calcium 2.31%, and chlorine
0.14%; mass density 1.044 g/cm3 with default mean excitation energy.
A 40 × 40 cm2 plane volume (1 mm size in depth) with a
0.5 × 0.5 mm2 scoring resolution was used to score in‐air and in‐water
lateral profiles of pencil beams in the TOPAS simulations. The statisti-
cal uncertainties were within ~2% for isodoses >0.1% level. A
40 × 40 × 40 cm3 cubic phantom with a 1 × 1 × 1 mm3 scoring reso-
lution was used to record three‐dimensional dose distributions. The
TOPAS simulation statistical uncertainties of energy deposition on the
central axis were less than 0.5%.
In order to recalculate complete patient treatment plans, we
developed an in‐house tool based on Matlab to convert the DICOM
plan from a commercial TPS (Eclipse 13.7, Varian Medical Systems,
Palo Alto, CA) to TOPAS proton emittance at the source plane. Both
physics (beam energy, spot positioning, MUs of each spot) and geo-
metrical information (range shifter information, gantry and couch
rotation) are included in TOPAS.
Before importing patient DICOM files into TOPAS, structures
such as the couch, anterior bolus, head bolus, and artifacts, were
replaced with overridden CT values in a manner identical to that of
our current clinical planning process. A conversion from HU to
human tissues (including elemental composition, weights, and den-
sity) was also implemented using the method described by Schneider
et al,37 with a correction factor to normalize the density in the MC
system to mimic the HU‐vs‐relative stopping power table in our
commercial planning system.1
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Finally, to demonstrate the application of such a TOPAS‐based
dose calculation platform, we applied it as a benchmark tool to
evaluate the dose calculation accuracy of a fast MC algorithm and
an analytical algorithm. The routine use of TOPAS in the clinic for
dose verification or treatment planning is significantly hindered by
its long computation time. Therefore, a fast MC algorithm, such as
MCsquare,16 has been developed for proton therapy in order to
accelerate the computation speed while preserving the accuracy of
a general purpose MC. MCsquare used in our study is a dedicated
fast MC algorithm embedded in the open Reggui platform (https://
openreggui.org/). To improve calculation performance, MCsquare is
optimized and limited to proton PBS simulations in a voxelized geom-
etry. Moreover, it is implemented to exploit both task and data paral-
lelisms of modern processors. The multiple Coulomb scattering model
proposed by Rossi and Greisen38 is employed in MCsquare. Elastic and
inelastic nuclear interactions are sampled from cross sections in ICRU
report 63.39 Heavy charged secondary particles are fully simulated by
scaling proton stopping powers using the particle charge and mass.
The same source model derived in previous sections is directly imple-
mented into MCsquare. The analytical algorithm in TPS used in this
work was Eclipse verison 13.7 (Varian Medical Systems, Palo Alto, CA)
with the proton convolution superposition (PCS) dose algorithm,40
which is a fluence‐dose calculation technique that calculates dose by
convolving the proton fluence with a dose kernel.41 One representa-
tive locally advanced liver cancer case and one complex locally
advanced lung case were simulated with approximately the same num-
ber of ~2 × 107 protons per field for each of the two MC algorithms,
as well calculated in the commercial TPS. The scoring resolution for
TOPAS and MCsquare were set the same as the imported CT
(0.98 × 0.98 × 3 mm3 for the liver patient and 1.17 × 1.17 × 3 mm3
for the lung patient), while a dose grid of 2.5 mm was set for the TPS.
For convenient comparison of the dose from TPS and MC, a Matlab‐
based open‐source package (OpenReggui), which can visualize CT,
structure and dose and calculate DVHs, was used. All treatment plans
for MC simulation were calculated on a LINUX‐based workstation with
72 cores (Intel Xeon E5‐2699 v3 Processor), while the TPS used a
Windows‐based server with 48 cores (Intel Xeon E7‐8857 v2
Processor).
3 | RESULTS
3.A | Source model characterization
3.A.1 | Beam optics
The change of spot size, σ, for the IBA dedicated PBS nozzle for
115 MeV and 210 MeV is shown in Fig. 2(a). We can observe that
the σ in the x direction first focuses (decreases) then subsequently
defocuses (increases) from upstream to downstream, while continu-
ously defocusing in y direction. This is due to the integrated focusing
effect of the two quadruples as well as less air scattering in the ded-
icated nozzle compared to universal nozzle. The spot sigma generally
decreases with energy, and the shape is more elliptical for lower
energy [Fig. 2(b)]. From 210 to 225 MeV, however, the spot sigma
unexpectedly increases. We speculate that this phenomenon is due
to better beam focusing at 210 MeV than at 225 MeV. Figure 2(c)
shows the dependence of σθ on energy, which decreases from
~6 mrad at 100 MeV to ~3 mrad at 210 MeV. This is comparable
with the values reported by Grevillot et al.10
3.A.2 | Depth‐dose curves and protons per MU
Figure 3 shows measured Bragg peak curves compared with those cal-
culated with TOPAS. Differences in R80 are generally less than 0.1 mm
on average; the mean point‐to‐point dose difference is always below
0.5%, while the peak‐to‐plateau ratio and FWHM difference are 0.4%
and 1 mm on average, respectively. It is worth mentioning that the
energy spread is a key parameter influencing both the peak‐to‐plateau
ratio and the FWHM: the peak‐to‐plateau ratio decreases while
FWHM increases with increasing energy spread.
Figure 4 shows the variation of energy spread and number of
protons per Monitor Unit (MU) with proton energy. The energy
spread decreases from 0.67% at 100 MeV to 0.28% at 225 MeV,
similar to values reported by Grevillot et al.28 The number of pro-
tons per MU increases from ~9E7 at 100 MeV to ~1.5E8 at
225 MeV, and is proportional to electronic proton stopping power
within 1%.
3.B | Validation of spot size
Figure 5 shows a comparison of measured and simulated spots at
various depths in Solid Water for five energies [Fig. 5(a)], and for
various air gaps following the range shifter for four energies [Fig. 5
(b)]. The principal component of proton beam scattering is due to
multiple Coulomb scattering, which directly impacts the spot size
variance along the depth in material and propagation through the air
after range shifter. Overall, TOPAS follows measurements very well,
with a difference of 0.1 ± 0.1 mm on average.
3.C | Validation of the halo
The primary transverse dose spread of each single spot is due to
MCS interactions within the medium and propagation through air, as
discussed in Section 3.B. Because of large angle scattering as well as
non‐elastic nuclear interactions, the halo can spread dose far away
from the beam center. The impact of the beam halo is particularly
pronounced at large field sizes. Figures 6(a) and 6(b) show the
dependence of FSF with depth in water without a range shifter for
115 and 225 MeV, respectively. For the low energy 115 MeV beam,
the FSFs remain approximately constant with depth; the difference
between 40 × 40 mm and 200 × 200 mm is approximately 3%. In
contrast, the difference between FSF of 40 × 40 mm and
200 × 200 mm can be as large as 11% at mid‐range5 for 225 MeV,
due to increased nuclear interactions with energy [Fig. 6(b)]. The
estimated uncertainties of the FSF measurements are below 0.4%
derived from eight repeated measurements of FSFs of 115 MeV at
isocenter in air.
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Figure 7 shows the change in FSF along the beam path first in
air (to an air gap of 195 mm) and then in water, for 115 and
225 MeV, respectively, with a range shifter in place. At 115 MeV,
we observe that the halo increases as it propagates though air due
to large scattering angle from interactions within the range shifter.
The difference between FSF at 40 × 40 mm and 200 × 200 mm can
be as large as 15% at an air gap of 195 mm. Compared to 115 MeV,
FSF at 225 MeV vary less due to the decrease in scattering angle
with energy. The significant variance in the halo, especially for low‐
energy protons, suggests that comprehensive modeling of spots after
the range shifter is a prerequisite for commercial TPS. The difference
between measured and simulated FSFs as a function of energy, at
depths both close to surface and near the Bragg peak, are
summarized in Fig. 8. FSF simulations agree with measurement
within 2.2% for each of the scenarios shown.
3.D | Validation of dose distribution in water
The measured and simulated depth doses along the central axis for
three different SOBPs, both without and with a range shifter, are
shown in Fig. 9. Simulations agree well with measured data, with a
maximum dose difference of less than 2.2% and a clinical range
agreement within 0.6 mm. Tables 1 and 2 list other dosimetric
parameters for the lateral dose profiles at mid‐range of SOBPs
with and without a range shifter. The 20–80% penumbra and half‐
widths of the shoulder at the 95% and 5% levels calculated by
F I G . 2 . (a): spatial beam spread distribution (spot size), σ, derived for the IBA dedicated PBS nozzle along beam path for 115 and 210 MeV,
respectively. (b): Spatial beam spread distribution (spot size), σ, derived at isocenter as a function of energy. (c): Angular spread distribution
(beam divergence) derived as a function of energy.
F I G . 3 . (a) Comparison of Bragg peak curves between TOPAS and measurements (b) the range, FWHM agreement, mean point‐to‐point and
peak‐to‐plateau ratio differences (TOPAS‐Meas).
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F I G . 4 . Gaussian energy spread (a) and number of protons per MU and the inverse of electronic proton stopping power in air (b) vs proton
energy for the IBA dedicated PBS nozzle.
F I G . 5 . Spot sigma (average of x and y directions) for single pencil beams as a function of depth in Solid Water® phantom (a), and as a
function of air gap following the range shifter (b).
F I G . 6 . (a) and (b): Comparison of measured (markers) and TOPAS (dashed lines) FSFs dependence with depth in water, with the water
phantom surface at isocenter for energies of 115 and 225 MeV (purple and “o” for 40 × 40 mm field size; green and “Δ” for 48 × 48 mm;
cyan and “+” for 96 × 96 mm field size; black and “*” for 200 × 200 mm field size).
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TOPAS agree with the measurements within 0.5, 1.5, and 1.2 mm
respectively.
3.E | Validation of dose distribution in the IROC
lung phantom
One‐dimensional dose profiles through the center of the planning
target volume for the IROC lung phantom are shown in Figs. 10(c)
and 10(d). Compared to the TPS, TOPAS simulations agree signifi-
cantly better with measurement in both the plateau, distal, and
penumbra regions. Because the proton fluence along the central
path of each pencil beam is predicted using the water‐equivalent
thickness therefore the spreading out of the spot proton fluence
due to divergent transport is underestimated when lung and air
exists in the beam path leading to significant underestimation of
penumbra by the TPS. Furthermore, the assumption of lateral homo-
geneity in ADC cannot accurately estimate the lateral fluence in a
heterogeneous medium, particularly when the heterogeneity is
within the Bragg peak region. The percentage of pixels passing the
7%/5 mm gamma analysis criteria for axial, sagittal, and coronal
planes and the point dose ratio between TLD measurements and
simulation for both TPS and TOPAS are shown in Table 3. It can be
observed that the gamma pass rate is improved significantly, from
66% to over 93% for TOPAS over the axial plane, while the sagittal
and coronal plane agreements were improved from below 85%, the
passing threshold, to over 98%. The output measurement results
showed an overestimation of dose to the center of the target by 4%
for TPS while TOPAS had a good agreement within 1% of measure-
ment. Although TOPAS has better general agreement with measure-
ment than the TPS, we can find TOPAS overestimates the dose in
F I G . 7 . Comparison of measured (markers) and TOPAS (dashed lines) FSF dependence along beam path in air and in water after the range
shifter for energies of 115 MeV (a) and 225 MeV (b) with the water phantom surface placed at an air gap of 195 mm, where the left side of
the perpendicular dashed line is in air and the right side is in water (purple and “o” for 40 × 40 mm field size; green and “Δ” for 48 × 48 mm;
cyan and “+” for 96 × 96 mm field size; black and “*” for 200 × 200 mm field size).
F I G . 8 . Percentage differences between calculated and measured FSF for three monoenergetic fields at two depths as a function of proton
energy without (a) and with (b) a range shifter. The red markers represent the results at the surface and the blue markers represent depths
close to the Bragg peak.
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the plateau region in Figs. 10(c) and 10(d), though the dose differ-
ence is still within 5%. Large‐dose differences can be observed in
the distal fall‐off region of the field along the left–right direction in
Fig. 10(c), which can be ascribed to a range difference. As this region
is still within the lung, with a relative stopping power ratio of ~0.31,
the 10 mm geometrical range difference is roughly equivalent to a
3.1‐mm water equivalent thickness (WET) difference, that is, 1.9% of
the nominal range (166 mm) of the lateral left–right field. Therefore,
F I G . 9 . Central axis depth doses
calculated by TOPAS (dashed line) are
compared with measurements (marker) for
three proton beams of varying ranges and
modulation at a field size of 96 mm
without (a) and with (b) a range shifter.
Depth dose of R120M40 was renormalized
by multiplying 105% to avoid overlap with
R200M100.
TAB L E 1 Comparison of dosimetric parameters of lateral dose profiles at mid‐range of SOBPs without the range shifter, measured using the
Lynx in a Solid Water® phantom.
SOBP
Penumbra 20%–80% (mm)
Half‐width of 95% maximum
(mm)
Half‐width of 5% maximum
(mm)
Measured TOPAS Measured TOPAS Measured TOPAS
R120M40 8.0 8.3 41.7 40.8 58.3 59.2
R200M100 7.8 8.1 39.7 39.2 56.5 57.3
R305M100 10.2 10.7 37.4 36.0 59.8 61.0
TAB L E 2 Comparison of dosimetric parameters of lateral dose profiles at mid‐range of SOBPs with the range shifter, measured using the Lynx
in a Solid Water® phantom.
SOBP
Penumbra 20%–80% (mm)
Half‐width of 95% maximum
(mm)
Half‐width of 5% maximum
(mm)
Measured TOPAS Measured TOPAS Measured TOPAS
R60M50 9.1 9.4 35.0 34.1 54.4 55.2
R150M100 9.1 9.3 36.3 35.1 55.8 56.8
R240M100 11.6 11.8 37.7 36.6 62.9 63.9
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we think the profile differences between TOPAS and measurements
are not significant. The range uncertainty in TOPAS is likely caused
by the uncertainty in CT and material conversion. The measurements
add additional uncertainty due to film dosimetry and experimental
setup.
3.F | Application examples
Figure 11 shows MC calculations for a representative plan of a
patient with primary liver cancer originally planned using the com-
mercial TPS. The plan consisted of two anterior oblique (10° and
280°) fields. The TOPAS plan is shown in one representative axial
plane in Fig. 11(a) with the iCTV and liver (total liver minus GTV)
DVHs in Fig. 11(b). The coverage (D95, the maximum dose that cov-
ers 95% of the target volume) and the overdose (D02, the maximum
dose that covers 2% of the target volume) indices are within 1%
F I G . 10 . (a, b) Axial and sagittal view of the proton lung phantom with gantry angle orientation indicated. (c, d) Dose profile through the
center of the planning target volume (PTV) in the left‐right and inferior–superior directions. Film measurements are shown in black, the analytic
pencil beam algorithm in blue, TOPAS.
TAB L E 3 The gamma passing rate of TPS and TOPAS in
comparison with film measurement embedded in IROC
anthropomorphic left lung phantom and dose ratio of TLD
measurements to TPS/TOPAS. 5 mm/7% criteria were used in
gamma comparison.
Film plane (gamma Index) TLD
Axial Coronal Sagittal Superior Inferior
ADC 66% 82% 83% 0.96 0.96
TOPAS 93% 98% 99% 0.99 0.99
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among different algorithms. Figures 11(c) and 11(d) show the differ-
ences in absolute dose between TOPAS and MCsquare and between
TOPAS and the TPS, respectively. This demonstrates that dose dif-
ference among algorithms of over 99.5% voxels in the iCTV are
within 3% of the prescription dose for the geometrically simple liver
case. In general, there is good agreement in output, penumbra and
range among the commercial TPS, MCsquare, and TOPAS for this
liver case.
Figure 12 shows MC calculations for a representative plan of
a patient with locally advanced non‐small cell lung cancer originally
planned using the commercial TPS. This plan consisted of one
posterior field and one left posterior oblique (160°) field. The dif-
ferences are reflected in the DVH analysis [Fig. 12(b)]. In this
case, coverage (D95) was degraded by 4.3% between TPS and
TOPAS while the difference between MCsquare and TOPAS is
less than 0.6%. Hot spots (D02) are 106.7%, 110.3%, and 109.9%
for TPS, MCsquare, and TOPAS, respectively. Figures 12(c) and
12(d) show the absolute dose difference between TOPAS and
MCsquare and between TOPAS and the TPS, with 99.2% of vox-
els in the iCTV within 3% of the prescription dose for
[MCsquare– TOPAS] while only 74.1% for [TPS–TOPAS] 42. While
MCsquare and TOPAS agree well, hot and cold spots can be
observed in the TPS–TOPAS comparisons. These discrepancies are
due to proton propagation through the tissue–lung interface,
where the TPS cannot address large heterogeneities well.
The average computational time for the two plans was ~4 h and
~5 min for TOPAS and MCsquare, simulating 4 × 107 protons on
our workstation, and ~30 s for the TPS, respectively. Although, more
detailed validation work is still needed to implement MCsquare clini-
cally, the very short computation time of MCsquare would make
such a Monte Carlo system compatible with clinical routine.
Although the computational time for MCsquare has been signifi-
cantly reduced, more detailed validation work needs to be done
before MCsquare can be applied in the clinic.
F I G . 11 . Recalculation of a liver treatment plan using TOPAS and MCsquare. (a) the dose color wash calculated by TOPAS, and (b), the DVH
comparison for the three methodologies. Dose differences between MCsquare and TOPAS, and between TPS and TOPAS, are shown in a
representative axial plane in (c) and (d), respectively. The visible structure is iCTV (red).
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4 | DISCUSSION
When a beam propagates through the range shifter, protons lose
energy through Coulomb interactions with electrons and through
nuclear collisions that result in the production of secondary neu-
trons, protons, gamma‐rays, and other particles that are transported
away from the direction of the incident beam. Table 4 shows the
number of secondary particles propagating through the range shifter
relative to protons simulated at source plane for two representative
energies, 115 and 225 MeV. The mean energy of each type of parti-
cle is also listed. As expected, due to the large water‐equivalent
thickness (74.1 mm) of the range shifter, the loss of primary protons
is large, 8.96% for 115 MeV while 7.57% for 225 MeV, and
decreases with increasing energy. Meanwhile, the number of sec-
ondary protons increases with increasing energy. This is because
both lower energy primary and secondary protons have a higher
probability to undergo large‐angle scattering which leads to absorp-
tion in the range shifter or causes them to miss the 0:4 0:4 m2
scoring plane.
With a range shifter and a large air gap, the broadening of the
spot due to MCS in the range shifter quickly becomes very large,
F I G . 12 . Recalculation of a lung treatment plan using TOPAS and MCsquare. (a) the dose color wash calculated by TOPAS, and (b), the DVH
comparison for the three methodologies. Dose differences between MCsquare and TOPAS, and between TPS and TOPAS, are shown in a
representative axial plane in (c) and (d), respectively. The visible structure is iCTV (red).
TAB L E 4 Number of secondary particles at the downstream surface
of the range shifter in percentage relative to protons simulated at
source plane.
115 MeV 225 MeV
Relative
number (%) E (MeV)
Relative
number (%) E (MeV)
Primary protons 91.04 54.6 92.43 193.5
Secondary protons 1.33 28.4 4.86 104.6
Neutrons 4.62 22.9 5.57 65.1
Electrons 5.55 0.1 4.82 0.2
Photons 5.34 1.1 5.15 1.0
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with the halo masking the primary spot due to the secondary parti-
cles. Given the validation results of the spot size and field size factor
presented in Sections 3.B and 3.C, TOPAS is capable of accurately
modeling MCS and nuclear interactions, even with protons propagat-
ing through a large air gap following range shifter. Figures 13(a) and
13(b) present the calculated dose profiles (solid line) for single spots
as they evolve from air gaps of 5 to 150 mm following the range
shifter, for 115 and 225 MeV, respectively. We can observe that the
halo extends well beyond the primary component (dashed line) as air
gap increases, leading to a significant deviation from a Gaussian pro-
file; it is useful to point out that the halo is not apparent on a linear
scale. Figure 13 also shows the fractional integrated dose as a func-
tion of radius, normalized to an integration radius of 200 mm. One
typically considers the dose contribution beyond three standard
deviations of the spot size as that attributed as indirect dose contri-
bution from halo (due to large‐angle protons and secondary particles
resulting from nuclear interactions).10 The largest spot size is 7.4 mm
for 115 MeV at air gap of 150 mm; hence, the direct dose contribu-
tion is limited to approximately 22.2 mm. The collected fraction
beyond a 40 mm radius, therefore, is mainly representative of halo
contribution which increases from 5.3% to 17.5% and from 9.3% to
16.0% with an air gap increasing from 5 to 150 mm for 115 and
225 MeV, respectively.
It is crucial, therefore, to provide an accurate spot profile and to
account for secondary particles to model the large contribution and
significant variance of halo when range shifter is used. Shen8 has
proposed an efficient and accurate method of using multiple FSF
measurements to characterize the proton profile with fixed range
shifter and therefore configure the TPS. We believe that with a well
validated Monte Carlo platform, use of Monte Carlo calculated dose
profile can provide an alternative and efficient method for TPS/range
shifter commissioning. A Monte Carlo based method would be par-
ticularly valuable and convenient if a multi‐thickness range shifter
with different materials is used.42–44
F I G . 13 . r(a, b) present the comparison of the lateral profile along the X axis, with data inset plotted on a linear scale and (c, d) present fractional
integrated dose as a function of radius at air gaps of 5 mm (blue), 75 mm (red), and 150 mm (black) for 115 and 225 MeV, respectively.
570 | HUANG ET AL.
5 | CONCLUSIONS
In this paper, we have constructed an accurate TOPAS pencil beam
scanning proton therapy dose model and validated it by detailed mea-
surements of single spots, FSFs, and SOBPs, both without and with a
range shifter, as well as a credentialing lung phantom. Results for two
representative clinical treatment cases demonstrate the limitations of a
commercial TPS dose calculation in situations of highly heterogeneous
geometries. Such amodel can provide a clinic with an efficient and inde-
pendent check for patient specific QA as well as for benchmarking of
other fast MC dose calculation engines under development. Using an
independent MC code, we can more efficiently commission ADC engi-
nes by reducing the measured data required for halo modeling, espe-
cially when range shifters of multiple thicknesses are employed.
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